Lupo Mary P, Smith Stacy R, Thomas Jane A, Murphy Diane K, Beddingfield Frederick C
New Orleans, La.; and San Diego and Santa Barbara, Calif. From The Lupo Center for Aesthetic and General Dermatology; Therapeutics Clinical Research; University of California, San Diego; and Allergan, Inc.
Plast Reconstr Surg. 2008 Jan;121(1):289-297. doi: 10.1097/01.prs.0000294968.76862.83.
With the baby boomer generation firmly ensconced in middle age and the ubiquity of botulinum toxin type A, nonsurgical facial rejuvenation is becoming increasingly prevalent. As this generation continues to age, products with greater therapeutic power to correct aging changes will be in growing demand.
A multicenter, double-blind, randomized, within-subject, controlled study was conducted comparing Juvéderm Ultra Plus hyaluronic acid filler with bovine collagen. A subset of subjects classified as having treatment for severe nasolabial folds is presented in this article. Subjects received Juvéderm Ultra Plus in one severe nasolabial fold and Zyplast collagen in the other nasolabial fold; up to two touch-up treatments were allowed at 2-week intervals. Nasolabial fold severity was evaluated every 4 weeks for 24 weeks using a five-point scale. Treatment site reactions and adverse events were also recorded. A complimentary treatment was offered at the end of the trial, with effectiveness evaluations just before retreatment and up to 48 weeks after repeated treatment for a subset of subjects.
Of the 87 subjects, most were female Caucasians, but all Fitzpatrick skin types were represented (36 percent types IV through VI). At 24 weeks, 96 percent of nasolabial folds treated with Juvéderm had maintained clinically significant correction, and 81 percent maintained the correction for 1 year or more. Results were similar for those subjects with follow-up through 48 weeks after repeated treatment. The median volume required for repeated treatment with Juvéderm was significantly less than that for initial treatment (0.7 ml versus 1.6 ml).
Juvéderm Ultra Plus provides correction of severe nasolabial folds through 1 year or more.
随着婴儿潮一代步入中年，A型肉毒杆菌毒素广泛应用，非手术面部年轻化日益普遍。随着这一代人持续衰老，对具有更强治疗功效以矫正衰老变化的产品需求将不断增加。
开展了一项多中心、双盲、随机、受试者自身对照研究，比较乔雅登极致透明质酸填充剂与牛胶原蛋白。本文呈现了一部分被归类为接受严重鼻唇沟治疗的受试者。受试者一侧严重鼻唇沟注射乔雅登极致，另一侧注射Zyplast胶原蛋白；每2周可进行至多两次补打治疗。每4周使用五点量表评估鼻唇沟严重程度，为期24周。同时记录治疗部位反应和不良事件。试验结束时提供免费治疗，部分受试者在再次治疗前及重复治疗后长达四十八周进行疗效评估。
87名受试者中，多数为白人女性，但涵盖了所有Fitzpatrick皮肤分型（IV至VI型占36%）。24周时，96%接受乔雅登治疗的鼻唇沟维持了具有临床意义的矫正效果，81%维持矫正效果达一年或更长时间。重复治疗后随访至48周的受试者结果相似。乔雅登重复治疗所需的中位注射量显著低于初次治疗（0.7毫升对1.6毫升）。
乔雅登极致可有效矫正严重鼻唇沟，效果持续一年或更长时间。
